STOCK TITAN

Cytek BioSciences Inc - CTKB STOCK NEWS

Welcome to our dedicated news page for Cytek BioSciences (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek BioSciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cytek BioSciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cytek BioSciences's position in the market.

Rhea-AI Summary
Cytek Biosciences, Inc. appoints William McCombe as CFO, reaffirms 2024 revenue guidance of $203 million to $213 million with expected positive net income. McCombe brings extensive experience from leading technology companies and investment banking, positioning Cytek for sustainable growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
Rhea-AI Summary
Cytek Biosciences, Inc. (CTKB) expands its manufacturing capacity with a new facility in Wuxi, China, to meet the increasing demand for cell analysis solutions worldwide. The facility enables unique vendor relationships and in-house component manufacturing, enhancing Cytek's position in the industry. Cytek's product portfolio includes innovative cell analyzers and sorters, empowering scientists with advanced technology for research in various fields like immuno-oncology and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
Rhea-AI Summary
Cytek Biosciences reports strong financial results for Q4 and full year 2023 with revenue growth, new product launches, and strategic agreements. Despite increasing expenses, the company shows positive performance and outlines a growth outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.9%
Tags
earnings
Rhea-AI Summary
Cytek Biosciences, Inc. (CTKB) will be participating in several upcoming investor conferences, including the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, Raymond James 45th Annual Institutional Investors Conference, and TD Cowen 44th Annual Health Care Conference. The company will be presenting at these events, providing an opportunity for interested parties to access live and archived webcasts of the presentations on the 'Investors' section of the company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
conferences
-
Rhea-AI Summary
Cytek Biosciences, Inc. (CTKB) will report financial results for Q4 and full year 2023 on Feb 28, 2024, followed by a webcast conference call to discuss results, business developments, and outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
conferences earnings
-
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) has signed an agreement with the Centre for Genomic Regulation (CRG) and the Pompeu Fabra University (UPF) to drive technological innovation and accelerate discoveries for the scientific community. The collaboration aims to develop and test new methods using Cytek's Full Spectrum Profiling technology, providing researchers with continuous training on innovative developments in flow cytometry. Cytek's advanced cell analysis solutions offer a more comprehensive, accurate, and detailed analysis of cellular characteristics, leading to a better understanding of complex biological processes and the development of more effective therapeutic strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
none
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) expects its full-year revenue for 2023 to be near the high end of the company’s most recent revenue guidance range of $188 million to $192 million. The preliminary unaudited results were announced ahead of the 42nd Annual J.P. Morgan Healthcare Conference, where CEO Wenbin Jiang is scheduled to present and participate in a Q&A session on January 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.29%
Tags
none
-
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) to participate in the 42nd Annual J.P. Morgan Healthcare Conference. CEO Dr. Wenbin Jiang to present and participate in a Q&A session on January 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
conferences
-
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) introduces Cytek Orion™ reagent cocktail preparation system, saving time and resources, improving efficiency, and accuracy in laboratory workflow. The system simplifies and accelerates the preparation of multicolor antibody cocktails for flow cytometry, accommodating up to 60 individual reagent antibody conjugates. It is instrument-agnostic and seamlessly integrates with Cytek's ecosystem of complete solutions. The system reduces hands-on time, decreases costs due to potential human errors, and minimizes repetitive motion injuries, offering a smaller footprint and cost-effectiveness compared to competitive solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced its participation in the Piper Sandler 35th Annual Healthcare Conference in New York. The company's management will engage in a fireside chat on November 28th, accessible through a live and archived webcast on the 'Investors' section of the company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
conferences
Cytek BioSciences Inc

Nasdaq:CTKB

CTKB Rankings

CTKB Stock Data

877.83M
105.70M
8.79%
65.31%
6.5%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States
Fremont

About CTKB

Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches.